drugset / Trial / NCT00416455

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

NCT00416455 ↗

Phase 1/2 Completed 384 enrolled National Cancer Institute (NCI) NRG Oncology · collab
NaSingle-groupOpen-labelDiagnostic

Summary

This phase I/II trial is studying how well fludeoxyglucose F 18 PET scan, CT scan, and ferumoxtran-10 MRI scan finds lymph node metastasis before undergoing chemotherapy and radiation therapy in patients with locally advanced cervical cancer or high-risk endometrial cancer. Diagnostic procedures, such as a fludeoxyglucose F 18 positron emission tomography (PET) scan, computed tomography (CT) scan, and ferumoxtran-10 magnetic resonance imaging (MRI) scan, may help find lymph node metastasis in patients with cervical cancer or endometrial cancer.

Timeline

Start
2007-09
Primary completion
2014-09
Completion
2016-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Ferumoxtran-10 Diagnostic / imaging agent — Intravenous